ASB11: A Protein Interaction and Potential Drug Target (G140456)

Target Name: ASB11

NCBI ID: G140456

ASB11

ASB11: A Protein Interaction and Potential Drug Target

ASB11 (ASB11 variant 1) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the asparagine-rich protein (ARP) family, which includes a variety of structurally similar proteins that are involved in various cellular processes. One of the unique features of ASB11 is its ability to interact with the protein ASB12, which is also known as heat shock protein (HSP) 1.7. This interaction between the two proteins is of particular interest because it allows ASB11 to participate in the regulation of cellular processes that are closely tied to the stress response.

ASB11 has also been shown to play a role in the development and progression of a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its role in these processes has led to its potential as a drug target or biomarker.

One of the potential benefits of ASB11 as a drug target is its ability to interact with a variety of different proteins, making it a potentially versatile target for therapeutic intervention. For example, studies have shown that ASB11 can interact with proteins involved in cell signaling pathways , such as tyrosine kinase receptor, G protein-coupled receptor, and nuclear factor kappa B (NF-kappa-B) signaling pathways. This suggests that ASB11 may be a useful target for interventions aimed at modulating these signaling pathways, which are involved in a wide range of cellular processes, including inflammation, cell survival, and angiogenesis.

In addition to its potential as a drug target, ASB11 has also been shown to be a valuable biomarker for a variety of diseases. For example, studies have shown that ASB11 is expressed in a variety of tissues and that its levels can be affected by a variety of different factors, including stress, exercise, and disease. Its stability and/or alteration in these conditions may be an indicator of the underlying biological processes and could be used as a diagnostic or prognostic marker.

Another promising aspect of ASB11 is its ability to interact with HSP1.7, a protein that is involved in a variety of cellular processes, including stress response, DNA damage repair, and apoptosis. This interaction between ASB11 and HSP1.7 suggests that ASB11 may be involved in the regulation of these processes and may be a potential target for interventions aimed at modulating these processes.

In conclusion, ASB11 is a protein that has been shown to play a variety of roles in various cellular processes and has been linked to the development and progression of a variety of diseases. Its ability to interact with HSP1.7 and its potential as a drug target or biomarker make it an intriguing target for further investigation and may lead to new therapeutic interventions. Further research is needed to fully understand the role of ASB11 in these processes and to determine its potential as a drug or biomarker.

Protein Name: Ankyrin Repeat And SOCS Box Containing 11

Functions: May be a substrate-recognition component of a SCF-like ECS (Elongin-Cullin-SOCS-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins

The "ASB11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ASB11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets